INTRODUCTION
============

aspergilli cause a wide spectrum of infections including cutaneous manifestations, otomycosis, and invasive infections such as pulmonary aspergillosis and endocarditis. Pulmonary aspergillosis may range from invasive pulmonary aspergillosis (IPA) in severely immunocompromised patients to chronic necrotising aspergillosis in mildly immunocompromised populations. The risk of IPA appears to be much higher in hematopoietic stem cell transplant patients and in patients with leukemia, where the attributable mortality rate was 38.5 % according to a recent study ([@ref36]). *Aspergillus fumigatus* remains the predominant agent of IPA, followed by either *A. terreus* or *A. flavus* depending on the medical center. Recently, IPA due to *A. ustus* and other rare aspergilli such as *A. alliaceus* ([@ref7]), *A. lentulus* ([@ref5]) and *A. udagawae* ([@ref6]) have been reported.

The genus *Aspergillus* was originally divided into subgenera and groups ([@ref41]) but the current classification scheme replaces the designation "group" with "section" ([@ref16]) to conform to rules of the International Code of Botanical Nomenclature. Currently, the genus *Aspergillus* is classified into 7 subgenera that are in turn sub-divided into several sections comprised of related species ([@ref16]). Clinical microbiology laboratories rely heavily on morphology-based identification methods for *Aspergillus* species wherein diagnostic criteria include the recognition of asexual or sexual structures and their characteristics such as shape, size, color, ornamentation and/or mode of attachment. Unfortunately, numerous difficulties exist in such a phenotype-based scheme largely because these characteristics are unstable, and clinical aspergilli sometimes manifest atypically with slow sporulation and aberrant conidiophore formation. Additionally, members of the section *Fumigati* have overlapping morphological characteristics, with several genetically distinct species existing within a single morphospecies.

Clinically, identification of unknown *Aspergillus* clinical isolates to species may be important given that different species have variable susceptibilities to multiple antifungal drugs. Thus, knowledge of the species identity may influence the choice of appropriate antifungal therapy. For example, *in vitro* and *in vivo* studies have demonstrated that *A. terreus* isolates are largely resistant to the antifungal drug amphotericin B, *A. ustus* isolates appear to be refractory to azoles, and *A. lentulus* and *Petromyces alliaceus* have low *in vitro* susceptibilities to a wide range of antifungals including amphotericin B, azoles, and echinocandins (Balajee *et al.* [@ref5], [@ref7]). Comparative DNA sequence-based identification formats appear to be promising in terms of speed, ease, objectivity and economy for species identification. Multiple genes ranging from the universal ribosomal DNA regions ITS and the large ribosomal subunit D1-D2 to protein encoding genes such as the β-tubulin and calmodulin gene regions have been evaluated to delimit species within aspergilli.

In spite of the shift of fungal identification formats into the molecular arena as evidenced by numerous publications, there is no consensus on the gene/genes that can be used for species identification in the genus *Aspergillus.* As a first step, a group of experts met at the "International Workshop on *Aspergillus* Systematics in the Genomic Era" \[Utrecht, The Netherlands; April 2007\] and presented research data on species identification strategies available to identify aspergilli. Throughout the meeting, research pertaining to the utility of the ITS region for inter section level classification of *Aspergillus* was presented. The session "Species identification in the clinical setting" was proposed specifically to deliberate on the utility of comparative sequence analyses of protein coding loci for intra section level species identification. This communication is a report of the research findings presented at this session. At the end of the report, we present the recommendations proposed by the *Aspergillus* working group for inter species level recognition of clinically relevant aspergilli and for identification of species within the sections *Fumigati, Terrei, Usti* and *Emericella nidulans*.

Pathogenic species in *Aspergillus* section *Fumigati* and species delimitation based on polyphasic taxonomy
------------------------------------------------------------------------------------------------------------

The most common causative agent of aspergillosis is *A. fumigatus* with rare reports of invasive infections caused by species of *Neosartorya.* However, clinical isolates of *A. fumigatus* are not necessarily morphologically uniform, and mistaken identification of these taxa by morphological characteristics has occurred in the past. In order to develop diagnostic techniques, it is essential to clarify intra- and interspecies diversity in *A. fumigatus* and closely related species using robust techniques.

Recently, *A. lentulus* isolated from clinical specimens in the U.S.A. was described as a new species; members of this species were not able to survive at 48 °C, and this species has high *in vitro* MICs to several different classes of antifungals ([@ref5]). Members of this species were distinct from the other species in this section, which includes the varieties of *A. fumigatus*. Two additional new species, *A. fumigatiaffinis* and *A. novofumigatus*, had also been proposed ([@ref26]) by investigators who analyzed the species within the section *Fumigati* using a polyphasic approach that included phenotypic characters such as macro- and micro-morphology, growth temperature regimes, and extrolite patterns, and genotypic characters including RAPD-PCR and multi-locus sequence typing (MLST) of partial β-tubulin, calmodulin and actin genes. From these results, 30 species were accepted within the section *Fumigati* ([@ref25]) and their taxonomic positions are shown in [Fig. 1](#fig1){ref-type="fig"}. Although *A. fumigatus* is the predominant agent of aspergillosis, several species in the section have also been reported from clinical samples: *A. fumisynnematus* ([@ref51]), *A. lentulus* (Balajee *et al.* 2005), *A. viridinutans* species complex (Hong *et al.* [@ref26], [@ref25]; [@ref30]), *Neosartorya coreana* ([@ref25]; [@ref30]), *N fennelliae* (([@ref33]), *N. fischeri* ([@ref9]; [@ref20]), *N. pseudofischeri* (often as the anamorph *A. thermomutans* status) ([@ref4]; [@ref10]; [@ref35]), *N. spinosa* ([@ref45]; [@ref19]), *N. hiratsukae* ([@ref21]) and *N. udagawae* ([@ref6]). In the case of *N. coreana* and *N. fennelliae*, pathogenicity in humans has not been established yet.

Because of the re-evaluation of section *Fumigati* based on polyphasic methods, the molecular identification of the *A. fumigatus* isolates recovered as causative agents of mycosis in humans and animals at the Medical Mycology Research Center, Chiba University, Japan (MMRC) was investigated ([@ref51]). Several other species within the section Fumigati were also included in the analyses. The phylogenetic relationships among *A. fumigatus* and related species, including *Neosartorya* species, were analyzed by sequencing partial regions of the β-tubulin, hydrophobin and calmodulin genes. The gene regions were sequenced directly from the PCR products by using primer pairs Bt2a and Bt2b, rodA1 and rodA2, and cmd5 and cmd6, respectively. PCR products were sequenced with the BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems) on an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems) and phylogenetic analyses were performed by the maximum parsimony (MP) and Neighbour-joining (NJ) methods. Comparative analyses of tree topologies from MP and NJ analyses showed no differences, and the three trees based on the three loci were similar.

Results of this study showed that the species within the section *Fumigati* could be divided into five clades: clade I, typical strains of *A. fumigatus* including *A. fumigatus* var. *ellipticus* ([@ref41]) and *A. arvii* ([@ref1]); clade II, species including *A. lentulus* and *A. fumisynnematus* ([@ref28]); clade III, species including *A. fumigatiaffinis* and *A. novofumigatus*; clade IV, atypical strains of *A. fumigatus* including *A. viridinutans* [@ref31]; [@ref47]); and clade V, species including *A. brevipes, A. duricaulis* and *A. unilateralis*. Most of the examined strains from clinical specimens in Japan clustered together in clade I. The other strains from clinical specimens fell into clades II and IV, and none of the clinical isolates clustered within clades III and V.

Correlations among morphology, maximal growth temperatures, minimal inhibitory concentrations (MICs) of antifungal agents, and phylogeny of isolates within the section *Fumigati* were also analyzed ([Fig. 2](#fig2){ref-type="fig"}). Scanning electron microscopy examination of these isolates showed that the conidial ornamentations of isolates belonging to clades I and V were lobate-reticulate (Kozakiewicz 1989), while those of *A. viridinutans* were intermediate between lobate-reticulate and microtuberculate. All strains in clade II and the six variant isolates in clade IV (IFM 5058, 51744, 53867, 53868, 54302 and CBM FD-0143) had conidia with microtuberculate ornamentation. These six strains are very closely related to *N. udagawae* ([@ref27]), a heterothallic species isolated from soil in Brazil. However, mating between these strains and *N. udagawae* did not occur. It is often difficult to perform successful mating experiments on clinical isolates and fungi that have been routinely sub-cultured. Therefore these strains need to be investigated further before they are identified as the anamorphic state of *N. udagawae*.

The maximal growth temperatures and MICs of antifungal agents were also examined. The maximal growth temperatures of clades I, II, III, IV and V were above 50 °C, 45 °C, 45 °C, 42 °C and 42 °C, respectively. These phenotypic data may be useful for classification of species within *Aspergillus* section *Fumigati*. The isolates of *A. lentulus* demonstrated lower *in vitro* susceptibilities to amphotericin B than other isolates in section *Fumigati* ([@ref5]). In conclusion, these studies showed that species of *Aspergillus* section *Fumigati* were divisible into five distinct clades by molecular analyses. Further, results revealed good correlation between phylogenetic and phenotypic characteristics. Comparative sequence analyses of the *benA* and *cal* regions offered good resolution and can be used for species delimitation within the section *Fumigati*.

Molecular phylogeny in *Aspergillus* section *Terrei*
-----------------------------------------------------

Although *A. terreus* is a less common cause of invasive pulmonary aspergillosis when compared to *A. fumigatus*, infections due to these aspergilli appear to be increasing in frequency in certain hospitals worldwide ([@ref3]; [@ref34]). Infections due to these organisms are difficult to treat because of both *in vitro* and *in vivo* refractoriness of the organism to the antifungal drug amphotericin B. In addition, *A. terreus* often causes disseminated infection with increased lethality compared with other *Aspergillus* spp. ([@ref29]; [@ref44]; [@ref49]). *Aspergillus terreus* may be nosocomial in origin with potential reservoirs including construction activity, soil of potted plants, and water distribution systems in hospital environments ([@ref34]; [@ref2]; Flynn *et al.* 1993). In spite of the emerging threat due to this opportunistic pathogen, little is known about the genetic diversity and population structure of *A. terreus.*

Fig. 1.Phylogenetic tree of *Aspergillus* section *Fumigati* species inferred from Neighbour-Joining analysis of partial β-tubulin gene sequence. The shaded species have been reported from clinical environment.

*A. terreus* grows on potato dextrose agar at 25 °C as beige to buff to cinnamon brown colonies with reverse of the colony appearing yellow. Microscopically, conidial heads are biseriate and columnar with smooth walled conidiophores; conidia are globose and smooth. Globose, sessile, hyaline accessory conidia are frequently produced on submerged hyphae and are also produced *in vivo* during infection. Based on these phenotypical characteristics, *A. terreus* has been described as the only member of section *Terrei* and includes two varieties - *A. terreus* var. *africanus* and *A. terreus* var. *aureus*. However, molecular studies using the D1-D2 regions of the 28S RNA and the ITS regions (intergenic spacer regions 1 and 2 including the 5.8S rRNA) have indicated that this section should be expanded to include a number of other species ([@ref46]). Recently, a three locus phylogenetic approach using partial regions of the protein coding genes β-tubulin, calmodulin and enolase has been attempted to characterise the genetic variability of a large number of *A. terreus* isolates \[Balajee *et al.* in prep.\]. These results suggest that *A. terreus* var. *aureus* should be raised to species status and that several cryptic species probably exist within isolates identified as *A. terreus*. Interestingly, members of one cryptic species/clade included clinical isolates recovered predominantly as colonising agents in the immunocompetent population \[Balajee *et al.* in prep.\]. Although the results of this study demonstrated the usefulness of the three-locus sequence strategy for species recognition in section *Terrei,* comparative sequence analyses of the *benA* region alone appeared to be a good marker for species recognition in this section.

Fig. 2.Correlation among phylogeny, detailed morphology and maximal growth temperatures on *Aspergillus* section *Fumigati.* The letters L and M refer to the conidial ornamentation as observed by scanning electron microscopy.

*Emericella* species causing invasive infections
------------------------------------------------

Invasive infections caused by *Emericella* species are uncommon in humans. Infections due to *E. nidulans* (anamorph *Aspergillus nidulans*) appear to occur predominantly in patients with chronic granulomatous disease (CGD), a rare disorder of phagocytes in which absence of superoxide and hydrogen peroxide production in phagocytes predisposes patients to bacterial and fungal infections. Invasive *E. nidulans* infections in this patient group are associated with a higher mortality than those caused by *A. fumigatus* ([@ref11]). *E. nidulans* is rarely encountered in other patient populations at risk for aspergillosis, such as those with neutropenia from myeloablative chemotherapy or recipients of a hematopoietic stem cell transplant. The lung is the most common site of infection, followed by subcutaneous or liver abscess, suppurative adenitis, osteomyelitis, fungemia, cellulitis and meningitis ([@ref23]; [@ref50]).

The identification of *E. nidulans* in clinical microbiology laboratories is commonly based on the characteristic microscopic morphology. The conidiophore typically shows metulae and phialides arranged on the upper part of the flask-shaped vesicle. *E. nidulans* produces dark green conidia (asexual spores) on brown-tinged conidiophores, and characteristic cleistothecia contain asci with 8 purple-red ascospores ([Fig. 3](#fig3){ref-type="fig"}). Hülle cells, thickened large cells associated with cleistothecia, are often abundant in *E. nidulans*. Another species within the genus *Emericella* that causes infection in humans is *E. quadrilineata*, which was reported to cause onychomycosis in one patient and sinusitis in two patients with hematological malignancy ([@ref13]; [@ref22]; [@ref40]). The morphologic features that distinguish *E. nidulans* from *E. quadrilineata* can be detected only by electron microscopy: the ascospores of *E. nidulans* have two longitudinal crests, while *E. quadrilineata* has four short equatorial crests.

Fig. 3.Scanning electronmicroscopy of ascospores of *Emericella* species. A. *E. nidulans*. B. *E. echinulata.* C. *E. quadrilineata.* D. *E. rugulosa*. Scale bars = 5 μm.

A recent cluster of infections caused by *Emericella* species involving four patients was found to be due to *E. quadrilineata* based on sequence-based analysis of ITS1 and ITS2 regions \[Verweij *et al.* in prep.\]. Morphologically, the isolates were identical to *E. nidulans*. The identification of the strains involved in the cluster was further confirmed to be *E. quadrilineata* by sequence analysis of partial regions of the β-tubulin and the calmodulin genes \[Verweij *et al.* in prep.\]. In addition, several strains from the collection of the Centraalbureau voor Schimmelcultures were included in the study as well as clinical *E. nidulans* and *E. quadrilineata* isolates from published cases or private culture collections (Dotis *et al.* 2004). Based on the sequence-based analysis, several isolates were reclassified. The availability of molecular techniques in addition to morphological identification was shown to describe a role of *E. quadrilineata* as opportunistic fungal pathogen. The use of these techniques will help to identify and discriminate more accurately within the current fungal species and give more insight into the pathogenesis of fungal infection.

Pathogenic species in section *Usti*
------------------------------------

*A. ustus* is a world-wide occurring species commonly found in food, soil and indoor environments ([@ref42]). *Aspergillus ustus* is also isolated from clinical specimens; however, invasive infections caused by this species are uncommon. In the review by Panackal *et. al*. ([@ref37]), 21 documented cases of human infection were reported in the literature. Since this review, two more studies, a case of fungal endophthalmitis and a cluster of eye infections, have been published ([@ref43]; [@ref52]). The true incidence of infections caused by this species is probably higher than reported, as there are cases where the fungus has not been identified or other instances where the organism was identified but remains unpubl. ([@ref8]). The mortality associated with invasive aspergillosis caused by *A. ustus* seems strikingly high - of the 22 reported cases only 6 patients survived. One main reason for this high mortality rate could be the decreased susceptibilities of *A. ustus* to various antifungal drugs. *In vitro* susceptibility testing showed that this species has decreased susceptibilities to the antifungal drugs amphotericin B, caspofungin, itraconazole, voriconazole and posaconazole but is susceptible to the allylamine terbinafine ([@ref52]; [@ref17]; [@ref18]; [@ref38]).

*A ustus* (Bainier) Thom and Church (1926), described in 1881 by Bainier as *Sterigmatocystis usta*, was placed by Thom and Raper together with *A. granulosus*, in the *A. ustus* group. This group was revised by Raper and Fennell, who used a broad description of *A. ustus* and added *A. puniceus, A. panamensis, A. conjunctus*, and *A. deflectus*. The use of the name "groups", a category without nomenclatural standing, was abandoned, and infrageneric taxa were formalised. Subgenera and sections were created and *A. ustus* became the type species of section *Usti*, which was placed in the subgenus *Nidulantes* ([@ref16]). Peterson ([@ref39]) compared this phenotype-based classification system with the phylogenetic relationships based on the D1 and D2 regions of the large subunit ribosomal RNA (lsu-DNA). These data show that the type strain of *A. ustus* (and therefore also the section *Usti*) was in the subgenus *Nidulantes*. Because the entire section *Usti* branched between *Emericella* species, *Usti* was deleted and placed in section *Nidulantes*. However, the invalidation of section *Usti* by Peterson is rejected here since multiple sections can be linked to one teleomorph, and since the species also form a distinct clade within the subgenus *Nidulantes*. Based on the study of Peterson ([@ref39]), *A. ustus, A. puniceus* and *A. pseudodeflectus* are true members of the section *Usti*, while *A. deflectus* is tentatively placed in section *Nidulantes* and *A. panamensis* and *A. conjunctus* are in section *Sparsi*.

Of all the members in the section *Usti, A. ustus* is most often reported to be a causal agent of invasive infection, whereas *A. puniceus* and *A. pseudodeflectus* have never been mentioned in relation with infections. Only one report in available about *A. granulosus,* where this organism was described as the causal agent of a disseminated infection in a cardiac transplant patient ([@ref14]). A MLST study using the partial regions of β-tubulin, calmodulin and actin genes showed that *A. ustus* strains received from multiple centers ([@ref37]; [@ref52]; [@ref48]) revealed the presence of a new species *A. calidoustus* (**sp. nov.**) from predominantly clinical samples \[Varga *et. al*., unpubl. data\]. Phenotypic differences between *A. ustus* and *A. calidoustus* are easy to recognise, since the latter grows rapidly at 37 °C, while the former does not. Nevertheless, other undescribed species, which are also able to grow at 37 °C, are present in section *Usti* and the occurrence of these species in clinical samples remains unknown. Thus, identification solely based on morphology appears difficult and unreliable. An additional problem with members of section *Usti* is that these species rarely cause invasive infections, which makes identification even more difficult. Combining all of above mentioned details, the use of morphology in combination with sequence data is recommended as an approach which will generate a less subjective and more reliable result.

Analyses of the D1-D2 sequences currently deposited in GenBank showed that two main clades are present in the section *Usti*. In one clade the type cultures of *A. ustus* (U29791; NRRL 275), *A. puniceus* (AY216673; [CBS 495.65](http://www.studiesinmycology.org/cgi/external_ref?access_num=495.65&link_type=CBS)) and *A. ustus* var. *laevis* are present (U29788; NRRL 1852); the other clade includes the types of *A. granulosus* (AF454165; [CBS 119.58](http://www.studiesinmycology.org/cgi/external_ref?access_num=119.58&link_type=CBS)) and *A. pseudodeflectus* (AF433123; NRRL 6135). However, the D1-D2 region does not have enough variation for species delimitation. The presence of these two main clades is also confirmed by a phylogenetic analysis of the ITS region of the ribosomal RNA (Varga et. al., unpubl. data). Although identification of medically important aspergilli based on ITS sequence data is more reliable than that based on D1-D2 data ([@ref24]), it is also known that the genetic variability within the ITS region is not sufficient and that some *Aspergillus* species share identical sequences. This is also the case within the section *Usti*, where *A. pseudodeflectus* and *A. calidoustus* could not be discriminated on ITS data alone \[Varga *et al.* in prep.\]. For correct species identification within this section, it is recommended to use the protein coding genes rather than ITS or D1-D2 data. Partial regions of β-tubulin, calmodulin and actin genes were tested and gave good resolution and are therefore excellent identification markers within the section *Usti*.

RECOMMENDATIONS
===============

The preceding presentations clearly demonstrate that a multi locus sequence identification method where multiple genes (or portions there of) are sequenced and the resultant data are analyzed by phylogenetic methods is a robust strategy for species recognition within the genus *Aspergillus*. However, this methodology involves significant cost and phylogenetic expertise that are limiting factors in most clinical microbiology laboratories. Additionally, consideration should also be given to the fact that most of these isolates may not be true causative agents of disease and therefore may not warrant species level identification in a diagnostic laboratory. Taken together, a universal single marker that would rapidly and accurately identify *Aspergillus* isolates to the species level would help support diagnostic microbiology laboratories in their routine identification efforts. Comparative sequence-based methods are finding a place in the clinical microbiology laboratory for fungal species identification, and there is a need for a consensus recommendation for such global markers that can be used with confidence for this purpose.

Recently, the international group of experts that gathered for the workshop entitled "*Aspergillus* Systematics in the Genomic Era" reviewed research data presented from research groups worldwide on recent genomic investigations, secondary metabolite analyses, multi locus phylogenetic analyses of the genus *Aspergillus,* and sequence based identification schemes for previously recognised human pathogens within the genus. Deriving from the entire proceedings of the workshop in general and from the session on clinically relevant aspergilli in particular, the following recommendations were proposed as a first step towards formulating a unified sequence-based identification scheme for the genus *Aspergillus.*

Although not discussed in this session, previous publications and research work presented elsewhere during the meeting revealed the utility of ITS region for identification of *Aspergillus* isolates to the section level. Thus, as a first recommendation, comparative sequence analyses of the ITS regions, specifically the ITS1 and ITS2 non-coding regions flanking the 5.8S rDNA, was suggested as an appropriate locus for identification of *Aspergillus* isolates to the level of subgenus/section. Use of the ITS sequence should be sufficient to place most isolates within the appropriate section, but will not provide sufficient sensitivity to discriminate among individual species within the section. Realising the limitations of the ITS regions to identify intrasection species, sequence comparison of the β-tubulin region for species identification within the section (discussed in detail throughout this manuscript) was proposed as the second recommendation.

The ITS region is a convenient universal marker for fungal species identification and most clinical microbiology laboratories still rely on morphology based identification; both these strategies will not identify species within the sections. Considering these two factors and to help support species reporting in clinical microbiology laboratories, the term "complex" was proposed as an alternate to "section". Thus, whether clinical microbiology laboratories rely on morphological identification methods or an ITS based sequencing strategy, it is advised to report species within the sections *Fumigati, Flavi, Nidulantes, Usti* and *Terrei* as "species complex", for instance, "*A. fumigatus* complex". Results reported in this manner should be interpreted as indicating the placement of the isolate within the species complex, but not necessarily indicating a species within that section. The microbiologist and the clinician can then jointly decide whether further DNA sequencing using a protein coding locus is required to identify the individual into a particular species within the section/complex. This information may be necessary when investigating an outbreak, when dealing with infections refractory to antifungal therapy, or when performing applied epidemiologic studies. In all cases, communication between the clinician and the microbiologist is critical to provide results that benefit patient care with the highest value and the least cost.

It must be remembered that these are tentative recommendations that are based on research data available at this time. It should also be reiterated that comparative sequence analyses should be used in tandem with morphological examination for an identification scheme to be successful. We believe that these recommendations will help stimulate further discussion, encourage validations of appropriate loci for comparative sequence strategies, and focus research studies on the clinical relevance of recovering these species from our patient populations.

The contributors to this session were: A. Balajee, Pathogenic species in *Aspergillus* section *Terrei*; T. Yaguchi, Pathogenic species in *Aspergillus* subgenus *Fumigati*; B. Hong, Speciation in *Aspergillus* subgenus *Fumigati*; P. Verweij, *Emericella* pathogens; J. Houbraken, Pathogenic species in section *Usti*.
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